STIGIFTNCT05723484
Comparing a Novel Point-of-care Cytokine Biomarker Lateral Flow Test With Nucleic Acid Amplification Tests for Detection of Sexually Transmitted Infections and Bacterial Vaginosis
An observational study of STI, run by University of Cape Town at 3 sites in 3 countries.
Trial summary
1. To evaluate the performance of a lateral flow POC test, namely the Genital InFlammation Test (GIFT), for identifying women with inflammatory STIs and BV, who are at higher risk of HIV infection and reproductive complications; 2. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women only
- Conditions the study is for
- STI
- What is being tested?
- GIFT Device
- Type of treatment
- Medical device
- How many people
- 675 participants
- Where
- 3 sitesin 3 countries
- Study dates
- 1 Jun 2023to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Adult
Study population: Diagnostic: Non-pregnant, sexually active women aged 18-35 years accessing family planning services. Integration: * Local or regional policy makers: maximum 36 * Healthcare professionals: maximum 40 * Pregnant and non-pregnant, sexually active women of 18-35 years attending family planning services: maximum 45 * Pregnant and non-pregnant, sexually active women of 18-35 years attending family planning services: up to 200 participants per site for discrete choice experiment * Data from pregnant and non-pregnant, sexually active women of 18-35 years attending family planning services recruited in diagnostic study * Healthcare workers from diagnostic study sites
Diagnostic Inclusion Criteria:
- 18-35 years old
- Willing and able to provide informed consent to participate in the study
- Self-reported to be sexually active
- Not pregnant (determined by pregnancy test)
- Accessing family planning service
Integration Inclusion Criteria:
For all: Willing and able to provide informed consent to participate in the study
User experiences/perceptions activity:
- Local or regional policy makers, programmers and other opinion leaders and decision makers
- Healthcare professionals at health facilities
- Women who are eligible for the diagnostic study (including pregnant and menstruating women), but who are not part of the diagnostic study
- 18-35 years old
- Willing and able to provide informed consent to participate in the study
- Self-reported to be sexually active
- Accessing family planning service diagnostic study
Discrete choice experiments:
- Women who are eligible for the diagnostic study (including pregnant and menstruating women), who are either part of, or not part of, the diagnostic study
- 18-35 years old
- Self-reported to be sexually active
- Accessing family planning service diagnostic study
Decision tree classification algorithm:
- Data from diagnostic study participants
Economic evaluation:
- Healthcare professionals at health facilities involved in GIFT device implementation able to complete timesheets
Diagnostic Exclusion Criteria:
- <18 years or >35 years
- Refusal by a participant to participate in the study
- Treatment for any STI/BV in the past 30 days
- Pregnancy
- Enrolled in a study which does not allow co-enrolment in other studies
Integration Exclusion Criteria:
For all: Not willing or able to provide informed consent to participate in the study
User experiences/perceptions activity:
- Non-relevant policy makers
- Healthcare professionals at health facilities not included in diagnostic study
Women who are:
- Part of the diagnostic study
- <18 years or >35 years
- Treated for any STI/BV in the past 30 days
- Pregnant
- Enrolled in a study which does not allow co-enrolment in other studies
Discrete choice experiments:
Women who are:
- <18 years or >35 years
- Treated for any STI/BV in the past 30 days
- Pregnant
- Enrolled in a study which does not allow co-enrolment in other studies
Decision tree classification algorithm:
- Participants for whom there are no diagnostic study data
Economic evaluation:
- Healthcare professionals not at study sites, not involved in GIFT device implementation, and/or not able to complete timesheets
Trial locations and contacts
3 sites in 3 countries.
3 sites in 3 countries
Madagascar1 site
Centre Hospitalier Universitaire Gynéco-Obstétrique de Befelatanana
Antananarivo
South Africa1 site
Desmond Tutu Health Foundation
Cape Town, Western Cape, 7975
About this study
Official title: A Multi-centre Diagnostic Study to Evaluate the Feasibility and Performance of the Genital InFlammation Test (GIFT)
- To evaluate the performance of a lateral flow POC test, namely the Genital InFlammation Test (GIFT), for identifying women with inflammatory STIs and BV, who are at higher risk of HIV infection and reproductive complications;
- To evaluate how the GIFT device can be integrated in a feasible, acceptable, and cost-effective way into routine care.
Read the detailed description
DIAGNOSTIC Study
Design:
The study is a multicentre, multidisciplinary, cross sectional, prospective clinically based research project.
The first component is a diagnostic study which will enrol 225 women attending family planning services in each of the three study sites in South Africa, Zimbabwe, and Madagascar. Vaginal samples from the women will be applied to the GIFT device and results will be compared with the composite NAAT reference test for STIs and Nugent score test for BV to determine the performance of the device to detect STIs/BV. Women will attend only one study visit but will be recalled for treatment if required.
The second component to develop a feasible, acceptable and economically feasible STI/BV management algorithm which includes the use of the GIFT device to be integrated into national guidelines (hereafter referred to as the "integration study") is composed of four activities with different study designs: 1.User experiences and/or perceptions of the GIFT device involving qualitative focus group discussions and in-depth interviews, and a quantitative questionnaire for health care professionals; 2. Discrete choice experiment; 3 Development of a decision tree classification algorithm; 4. Economic evaluation of the defined management algorithms.
Study Sites:
- Cape Town, South Africa; Desmond Tutu Health Foundation (DTHF) Masiphumelele
- Harare, Zimbabwe; Chitungwiza Primary Health Care Clinics
- Antananarivo, Madagascar; Centre Hospitalier Universitaire Gynéco-Obstétrique de Befelatanana
Diagnostic Device:
The GIFT device is an immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.
Diagnostic Study Objectives:
Primary objectives To assess the sensitivity and specificity of the GIFT device at the point-of-care in non-pregnant sexually active women aged 18-35 years accessing family planning services in South Africa, Zimbabwe, and Madagascar.
Secondary objectives To assess the predictive values of the GIFT device at the point-of-care in non-pregnant sexually active women aged 18-35 years accessing family planning services in South Africa, Zimbabwe, and Madagascar; To assess the performance of the GIFT device at the point-of-care in non-pregnant sexually active women aged 18-35 years accessing family planning services in each of the countries; To assess the performance of the device versus syndromic management without any laboratory testing (standard of care in South Africa, Zimbabwe, and Madagascar); To determine the robustness of the device by comparing results read by clinicians with those read by laboratory professionals, and with the results obtained using an automated reader; To evaluate the accuracy of the GIFT device by comparing the GIFT device results with ELISA (enzyme-linked immunosorbent assay) results using previously validated concentration cut-offs as the gold standard, including validation of the GIFT cytokine concentration cut-offs for each cytokine biomarker.
Exploratory objectives Determine if other determinants (such as intermediate microbiota (Nugent 4-6), age, parity, sexual activity) improve the prediction of STI/BV status in women; To use 16S rRNA gene sequencing and vaginal bacteria specific quantitative NAATs to evaluate the proportion of cases of genital inflammation explained by vaginal dysbiosis that was not diagnosed as an STI or BV by NAATs or Nugent scoring; To explore the performance of the device in the presence of vaginal Candida spp colonisation.
INTEGRATION Study To evaluate how the GIFT device can be integrated in a feasible, acceptable, and cost-effective way into routine care (the "integration study"), four activities will be conducted: 1. User experiences and/or perceptions of the GIFT device; 2. Discrete choice experiment; 3 Development of a decision tree classification algorithm; 4. Economic evaluation of the defined management algorithms.
Objectives:
Primary objective To evaluate how the GIFT device could be integrated into routine care.
Secondary objectives To qualitatively and quantitatively assess the user-experience, usability, and acceptability of the GIFT device at the point of care; To examine patient preferences for various STI management aspects (attributes) to inform the development of STI management algorithms that integrate the GIFT device; To generate algorithms that integrate the GIFT device to optimise case finding and STIs/vaginal infection management in women, using the complete dataset from the study; To determine the cost and budget impact of the identified screening or diagnostic algorithm with the GIFT device, and to model the cost- effectiveness of different strategies of integration of GIFT into care.
- Conditions
- STI
- Being tested
- GIFT Device
- Medical subject headings
- Sexually Transmitted Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GIFT DeviceDevice
The GIFT device - immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.
What is being measured
The primary outcome is the main question the study is designed to answer.
Estimates of sensitivity and specificity for the GIFT device
Detecting the presence of any STI or BV with 95% confidence intervals, using NAATs and Nugent scoring in a composite reference standard.
Measured: Start- quarter 1/2023; End- quarter 4/2023
How the GIFT device could be integrated into routine care
Integration into healthcare guidelines
Measured: Start- quarter 1/2023; End- quarter 4/2023
Secondary outcomes (10)
Positive and negative predictive values of the GIFT device
predictive values of the GIFT device in each country and likelihood ratios, using NAATs and Nugent scoring as a composite reference standard
Measured: Start- quarter 1/2023; End- quarter 4/2023
Overall sensitivity of NAAT and Nugent scoring
Specificity and predictive values in each country using NAATs and Nugent scoring
Measured: Start- quarter 1/2023; End- quarter 4/2023
Overall sensitivity
Specificity and predictive values in each country and likelihood ratios of syndromic management, using NAATs and Nugent scoring as composite reference standards
Measured: Start- quarter 1/2023; End- quarter 4/2023
Comparison of sensitivity, specificity, predictive values in each country and likelihood ratios calculated with both methods
GIFT device and syndromic management using NAATs and Nugent scoring as composite reference standards
Measured: Start- quarter 1/2023; End- quarter 4/2023
Positive and negative agreement proportion and Kappa coefficient between results readings of 1/clinician and technician
2/clinician and automated reader; 3/technician and automated reader
Measured: Start- quarter 1/2023; End- quarter 4/2023
Positive and negative agreement proportion and Kappa coefficient between results readings of GIFT device and cytokine ELISA measurements
GIFT device and cytokine ELISA measurements
Measured: Start- quarter 1/2023; End- quarter 4/2023
User experiences
Perceptions of GIFT device
Measured: Start- quarter 1/2023; End- quarter 4/2023
User preferences
different STI management strategies based on patient preferences for various attributes of STI management using GIFT device
Measured: Start- quarter 2/2023; End- quarter 1/2024
Optimal case finding and STI management strategies
Using diagnostic study results
Measured: Start: - quarter 1/2024; End- quarter 4/2024
Cost and budget impact
Economic evaluation for the budget impact analysis to create strategies of integrating the GIFT device into standard of care
Measured: Start- quarter 3/2023; End- quarter 2/2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2023
- Study start1 Jun 2023
- Primary completion31 Dec 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for STIStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 675 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Cape Town
- Sponsor type
- University, hospital or other
- Collaborators
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd, Desmond Tutu HIV Foundation, London School of Hygiene and Tropical Medicine, UMC Utrecht, Institut Pasteur, Institut Pasteur de Madagascar, Hitotsubashi University
- Responsible party
- Principal investigator, Jo-An Passmore, University of Cape Town
- Investigators
- Jo-Ann Passmore, Professor, Principal investigator, University of Cape Town
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05723484
- Sponsor's protocol ID
- GIFT_EDCTP-RIA2020I-3297
- Acronym
- GIFT
- Status last verified
- Aug 2025
- First submitted
- 27 Jan 2023
- Last updated
- 6 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: De-identified study data will be made available to the study team only.
Publications
Ramboarina S, Crucitti T, Gill K, Bekker LG, Harding-Esch EM, van de Wijgert JHHM, Huynh BT, Fortas C, Harimanana A, Mayouya Gamana T, Randremanana RV, Mangahasimbola R, Dziva Chikwari C, Kranzer K, Mackworth-Young CRS, Bernays S, Thomas N, Anderson D, Tanko FR, Manhanzva M, Lurie M, Khumalo F, Sinanovic E, Honda A, Pidwell T, Francis SC, Masson L, Passmore JA; GIFT study group. Novel point-of-care cytokine biomarker lateral flow test for the screening for sexually transmitted infections and bacterial vaginosis: study protocol of a multicentre multidisciplinary prospective observational clinical study to evaluate the performance and feasibility of the Genital InFlammation Test (GIFT). BMJ Open. 2024 May 1;14(5):e084918. doi: 10.1136/bmjopen-2024-084918.
PubMed 38692732
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-centre Diagnostic Study to Evaluate the Feasibility and Performance of the Genital InFlammation Test (GIFT)
- ClinicalTrials.gov ID
- NCT05723484
- Acronym / sponsor ID
- GIFT / GIFT_EDCTP-RIA2020I-3297
- Conditions
- STI
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 675 participants (actual)
- Lead sponsor
- University of Cape TownUniversity, hospital or other
- Collaborators
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd, Desmond Tutu HIV Foundation, London School of Hygiene and Tropical Medicine, UMC Utrecht, Institut Pasteur, Institut Pasteur de Madagascar, Hitotsubashi University
- Study start
- 1 Jun 2023 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 10 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- To evaluate the performance of a lateral flow POC test, namely the Genital InFlammation Test (GIFT), for identifying women with inflammatory STIs and BV, who are at higher risk of HIV infection and reproductive complications;
- To evaluate how the GIFT device can be integrated in a feasible, acceptable, and cost-effective way into routine care.
Detailed description
DIAGNOSTIC Study
Design:
The study is a multicentre, multidisciplinary, cross sectional, prospective clinically based research project.
The first component is a diagnostic study which will enrol 225 women attending family planning services in each of the three study sites in South Africa, Zimbabwe, and Madagascar. Vaginal samples from the women will be applied to the GIFT device and results will be compared with the composite NAAT reference test for STIs and Nugent score test for BV to determine the performance of the device to detect STIs/BV. Women will attend only one study visit but will be recalled for treatment if required.
The second component to develop a feasible, acceptable and economically feasible STI/BV management algorithm which includes the use of the GIFT device to be integrated into national guidelines (hereafter referred to as the "integration study") is composed of four activities with different study designs: 1.User experiences and/or perceptions of the GIFT device involving qualitative focus group discussions and in-depth interviews, and a quantitative questionnaire for health care professionals; 2. Discrete choice experiment; 3 Development of a decision tree classification algorithm; 4. Economic evaluation of the defined management algorithms.
Study Sites:
- Cape Town, South Africa; Desmond Tutu Health Foundation (DTHF) Masiphumelele
- Harare, Zimbabwe; Chitungwiza Primary Health Care Clinics
- Antananarivo, Madagascar; Centre Hospitalier Universitaire Gynéco-Obstétrique de Befelatanana
Diagnostic Device:
The GIFT device is an immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.
Diagnostic Study Objectives:
Primary objectives To assess the sensitivity and specificity of the GIFT device at the point-of-care in non-pregnant sexually active women aged 18-35 years accessing family planning services in South Africa, Zimbabwe, and Madagascar.
Secondary objectives To assess the predictive values of the GIFT device at the point-of-care in non-pregnant sexually active women aged 18-35 years accessing family planning services in South Africa, Zimbabwe, and Madagascar; To assess the performance of the GIFT device at the point-of-care in non-pregnant sexually active women aged 18-35 years accessing family planning services in each of the countries; To assess the performance of the device versus syndromic management without any laboratory testing (standard of care in South Africa, Zimbabwe, and Madagascar); To determine the robustness of the device by comparing results read by clinicians with those read by laboratory professionals, and with the results obtained using an automated reader; To evaluate the accuracy of the GIFT device by comparing the GIFT device results with ELISA (enzyme-linked immunosorbent assay) results using previously validated concentration cut-offs as the gold standard, including validation of the GIFT cytokine concentration cut-offs for each cytokine biomarker.
Exploratory objectives Determine if other determinants (such as intermediate microbiota (Nugent 4-6), age, parity, sexual activity) improve the prediction of STI/BV status in women; To use 16S rRNA gene sequencing and vaginal bacteria specific quantitative NAATs to evaluate the proportion of cases of genital inflammation explained by vaginal dysbiosis that was not diagnosed as an STI or BV by NAATs or Nugent scoring; To explore the performance of the device in the presence of vaginal Candida spp colonisation.
INTEGRATION Study To evaluate how the GIFT device can be integrated in a feasible, acceptable, and cost-effective way into routine care (the "integration study"), four activities will be conducted: 1. User experiences and/or perceptions of the GIFT device; 2. Discrete choice experiment; 3 Development of a decision tree classification algorithm; 4. Economic evaluation of the defined management algorithms.
Objectives:
Primary objective To evaluate how the GIFT device could be integrated into routine care.
Secondary objectives To qualitatively and quantitatively assess the user-experience, usability, and acceptability of the GIFT device at the point of care; To examine patient preferences for various STI management aspects (attributes) to inform the development of STI management algorithms that integrate the GIFT device; To generate algorithms that integrate the GIFT device to optimise case finding and STIs/vaginal infection management in women, using the complete dataset from the study; To determine the cost and budget impact of the identified screening or diagnostic algorithm with the GIFT device, and to model the cost- effectiveness of different strategies of integration of GIFT into care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Age groups
- Adult
- Study population
- Diagnostic: Non-pregnant, sexually active women aged 18-35 years accessing family planning services. Integration: * Local or regional policy makers: maximum 36 * Healthcare professionals: maximum 40 * Pregnant and non-pregnant, sexually active women of 18-35 years attending family planning services: maximum 45 * Pregnant and non-pregnant, sexually active women of 18-35 years attending family planning services: up to 200 participants per site for discrete choice experiment * Data from pregnant and non-pregnant, sexually active women of 18-35 years attending family planning services recruited in diagnostic study * Healthcare workers from diagnostic study sites
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GIFT DeviceThe GIFT device - immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes. | Device | – |
Primary outcome
Estimates of sensitivity and specificity for the GIFT device
Time frame: Start- quarter 1/2023; End- quarter 4/2023
Detecting the presence of any STI or BV with 95% confidence intervals, using NAATs and Nugent scoring in a composite reference standard.
How the GIFT device could be integrated into routine care
Time frame: Start- quarter 1/2023; End- quarter 4/2023
Integration into healthcare guidelines
10 secondary outcomes
Positive and negative predictive values of the GIFT device
Time frame: Start- quarter 1/2023; End- quarter 4/2023
Overall sensitivity of NAAT and Nugent scoring
Time frame: Start- quarter 1/2023; End- quarter 4/2023
Overall sensitivity
Time frame: Start- quarter 1/2023; End- quarter 4/2023
Comparison of sensitivity, specificity, predictive values in each country and likelihood ratios calculated with both methods
Time frame: Start- quarter 1/2023; End- quarter 4/2023
Positive and negative agreement proportion and Kappa coefficient between results readings of 1/clinician and technician
Time frame: Start- quarter 1/2023; End- quarter 4/2023
Positive and negative agreement proportion and Kappa coefficient between results readings of GIFT device and cytokine ELISA measurements
Time frame: Start- quarter 1/2023; End- quarter 4/2023
User experiences
Time frame: Start- quarter 1/2023; End- quarter 4/2023
User preferences
Time frame: Start- quarter 2/2023; End- quarter 1/2024
Optimal case finding and STI management strategies
Time frame: Start: - quarter 1/2024; End- quarter 4/2024
Cost and budget impact
Time frame: Start- quarter 3/2023; End- quarter 2/2024
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2025.
- Derived from this study: PubMed 38692732Ramboarina S, Crucitti T, Gill K, Bekker LG, Harding-Esch EM, van de Wijgert JHHM, Huynh BT, Fortas C, Harimanana A, Mayouya Gamana T, Randremanana RV, Mangahasimbola R, Dziva Chikwari C, Kranzer K, Mackworth-Young CRS, Bernays S, Thomas N, Anderson D, Tanko FR, Manhanzva M, Lurie M, Khumalo F, Sinanovic E, Honda A, Pidwell T, Francis SC, Masson L, Passmore JA; GIFT study group. Novel point-of-care cytokine biomarker lateral flow test for the screening for sexually transmitted infections and bacterial vaginosis: study protocol of a multicentre multidisciplinary prospective observational clinical study to evaluate the performance and feasibility of the Genital InFlammation Test (GIFT). BMJ Open. 2024 May 1;14(5):e084918. doi: 10.1136/bmjopen-2024-084918.
- Individual participant dataSharing planned: No. De-identified study data will be made available to the study team only.
Related trials for STI
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Active, not recruitingPhase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Immunization, HPV Infection
Enrolling by invitation
Promoting Aging and Thriving With HIV
HIV (Human Immunodeficiency Virus), Geriatric
RecruitingObservational study
Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide
HIV (Human Immunodeficiency Virus), Pregnancy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jo-Ann Passmore, Professor principal investigator
University of Cape Town
3 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of STI, run by University of Cape Town at 3 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Madagascar, South Africa, Zimbabwe. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Estimates of sensitivity and specificity for the GIFT device (time frame: Start- quarter 1/2023; End- quarter 4/2023). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05723484, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2025.